Patient Navigation May Benefit Patients with Breast Cancer
the Cancer Therapy Advisor take:
Patient navigation is the process of a joining a newly diagnosed patients with cancer with a health care professional who has been specifically trained to guide patients through the complex journey of diagnosis and cancer treatment.
According to a study recently published in the Journal of Clinical Oncology, patients with high-risk disease and minority patients may receive better breast cancer care if they are linked to a patient navigator.
The study used data from a previously published multicenter study funded by the National Cancer Institute that looked to identify the benefits of assigning patient navigators to recently diagnosed patients. Naomi Ko, MD, MPH, of the Boston University School of Medicine in Boston, Massachusetts, was a lead researcher on the study and highlights that the findings demonstrate a need to additional investigation.
Dr. Ko stated that the study showed that there may be a great benefit from assigning patient navigators to patients with cancer, but there is still significant research to be done to determine how and why patient navigation works.
The goal is to conduct research that makes it clear exactly who will benefit the most from patient navigation and in what situations in order to help patients who need that assistance.
Patient navigation may lead to better breast cancer care in high risk and minority women.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer